To further strengthen its full-industry-chain presence in the cell and gene therapy (CGT) sector, Cytode Biotechnology has recently officially introduced MaxCyte’s cGMP‑grade ExPERT™ GTx flow electroporation technology platform from the United States, while simultaneously deploying Saiqiao Biotechnology’s CellFAB One N fully automated cell preparation system. The synergistic roll‑out of these two platforms marks a critical step forward for Cytode Biotechnology in non‑viral vector gene editing, automated cell processing, and large‑scale commercial manufacturing, laying a solid foundation for delivering safer, more effective, and more accessible cell therapy products to patients worldwide.

Streamlining the commercialization process.
The MaxCyte ExPERT GTx platform empowers cell therapy.

MaxCyte ExPERT Electroporation Workflow

As the global leader in flow electroporation technology, MaxCyte’s ExPERT GTx system is the first cGMP‑certified, clinical‑grade, large‑volume flow electroporation platform. With superior transfection efficiency and cell viability, the platform seamlessly bridges the needs of research discovery, clinical studies, and cGMP commercial manufacturing, enabling linear scalability of the process. The world’s first approved CRISPR/Cas9 gene‑editing therapy, Casgevy, was made possible by leveraging the MaxCyte platform to achieve clinical‑scale cell production.

Fully closed end‑to‑end manufacturing
CellFAB One N enables automated preparation.

Serving as a strategic complement to the MaxCyte electroporation platform, Saiqiao Biotechnology’s CellFAB One N fully automated cell preparation system is purpose‑built for standardized manufacturing of cell‑based drugs. It integrates a complete workflow encompassing PBMC isolation, nanomagnetic bead sorting, activation and cultivation, viral transduction, and expansion and harvesting. By employing fully closed disposable consumables and automated process control, the system maintains sterility and markedly reduces manual intervention, ensuring consistent product quality and reproducible manufacturing across batches.

Versatile process capabilities
Establishing an end‑to‑end manufacturing system.

Currently, Cytode Biotechnology has established a comprehensive portfolio of cell therapy process equipment, covering a wide range of scenarios including cell banking, autologous and allogeneic cell therapy production, and supporting multiple technological routes such as viral vector transduction, non‑viral vector electroporation, and gene editing. The synergistic introduction of the MaxCyte electroporation platform and the CellFAB One N automated system will further enhance the company’s technological depth in non‑viral electroporation process development and clinical‑scale manufacturing, thereby accelerating the advancement of multiple pipeline candidates into clinical and commercial stages, and contributing “Cytode’s strength” to the high‑quality development of China’s cell therapy industry.